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Introduction
The Human Gene Mutation Database, with >7,000 mono-
genic disorders, reports that ~9% of all known disease caus-
ing variants (numbering >170,000) are located at or near 
splice sites (http://www.hgmd.cf.ac.uk/).1 In addition, it has 
been estimated that an additional ~20% of pathogenic vari-
ants affect splicing but are located at more distant locations 
in introns or in exons.2–4 Consequences of aberrant splicing 
include exon skipping, intron retention, cassette exon inclu-
sion, and use of cryptic splice sites.5–7 There are several ways 
in which cryptic splicing may be induced by a pathogenic 
variant. One possibility is the generation of a new intronic 
splice donor or acceptor site that outcompete a canonical 
splice site. Alternatively, a natural cryptic splice site may be 
present that is normally suppressed by a canonical splice 
site, but becomes the dominant splice site due to weakening 
of the canonical splice site by a pathogenic variant. Weak-
ening of a canonical splice site can be a consequence of 
pathogenic variants that disrupt conventional splicing ele-
ments, including the splice site itself,8 the polypyrimidine 
tract,9 branch point sequence,10 or variants that modulate the 
activity of exonic and intronic splicing silencer or enhancer 
elements11,12 (reviewed by Scotti et al.5). Another mechanism 
represents formation of a newly formed cryptic splice site 
at an exonic rather than intronic location. The location of a 
cryptic splice site in coding or noncoding RNA is likely impor-
tant because exons and introns are defined within the pre-
mRNA via interaction with distinct RNA binding proteins that 
may differentially affect cryptic splice site utilization. These 
include members of the SR and hnRNP families.13,14 How-
ever, for many disorders and gene variants, those that may 
affect splicing are poorly characterized.
Pre-mRNA splicing is regulated at several levels. Splice 
sites have short consensus sequences that are recognized 
by the spliceosome complex members, while additional, 
poorly defined sequences present in the introns and exons 
can modulate splice site choice. In addition, other mecha-
nisms can affect splicing including the speed of RNA pol II 
transcription, chromatin structure, histone modifications, 
alternative transcription start and termination sites, GC con-
tent, mRNA export, mRNA stability, and expression levels of 
critical splicing proteins.13,14 These are likely reasons why 
in silico prediction of splice site choice is difficult and experi-
mental testing is required to elucidate the effect of patho-
genic gene variants.
We have previously described a splicing assay that can be 
used for the detection and quantification of aberrant splicing in 
Pompe disease (OMIM232300).15 It is based on the analysis 
of all exons of the acid α-glucosidase (GAA) gene. Besides 
the detection of aberrant splicing that may be linked to the 
disease, this approach provides quantitative information on 
the extent of leaky wild type splicing, which is informative for 
disease severity, and on the splicing mechanism, which is 
required to design methods for splicing correction. Antisense 
oligonucleotides (AONs) provide a way to interfere with splic-
ing in a sequence-specific manner.16 AONs can be targeted 
to the pre-mRNA region of interest and they can repress the 
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While 9% of human pathogenic variants have an established effect on pre-mRNA splicing, it is suspected that an additional 
20% of otherwise classified variants also affect splicing. Aberrant splicing includes disruption of splice sites or regulatory 
elements, or creation or strengthening of cryptic splice sites. For the majority of variants, it is poorly understood to what extent 
and how these may affect splicing. We have identified cryptic splicing in an unbiased manner. Three types of cryptic splicing 
were analyzed in the context of pathogenic variants in the acid α-glucosidase gene causing Pompe disease. These involved 
newly formed deep intronic or exonic cryptic splice sites, and a natural cryptic splice that was utilized due to weakening of a 
canonical splice site. Antisense oligonucleotides that targeted the identified cryptic splice sites repressed cryptic splicing at 
the expense of canonical splicing in all three cases, as shown by reverse-transcriptase-quantitative polymerase chain reaction 
analysis and by enhancement of acid α-glucosidase enzymatic activity. This argues for a competition model for available splice 
sites, including intact or weakened canonical sites and natural or newly formed cryptic sites. The pipeline described here can 
detect cryptic splicing and correct canonical splicing using antisense oligonucleotides to restore the gene defect.
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activity of a splicing motif. The clinically most advanced exam-
ples are enhancement of exon inclusion of survival of motor 
neuron 2 (SMN2) pre-mRNA in spinal muscular atrophy,17 
and exon skipping of the dystrophin pre-mRNA in Duchenne 
muscular dystrophy (DMD).18 Other preclinical examples 
include modulation of splicing in Hutchinson-Gilford progeria 
syndrome19 and type I Usher syndrome.20 The developments 
for enhancing cellular uptake using conjugation of AONs to 
cell penetrating peptides21–23 and via coadministration of hex-
ose24 is expected to further stimulate the clinical development 
of AON-based splicing modulation.
Here, we present a pipeline in which characterization of 
aberrant splicing in Pompe disease is first performed using 
a generic splicing assay.15 The information obtained is then 
used to design an AON based on inhibition of cryptic splic-
ing, and the AON is tested in patient-derived fibroblasts. 
Pompe disease is an autosomal recessive disorder caused 
by variants in the GAA gene and results in lysosomal glyco-
gen accumulation that predominantly affects skeletal muscle 
in the childhood/adult onset form of the disease.25 Currently, 
enzyme replacement therapy is available, but there are sev-
eral reasons to develop alternative therapies, including the 
heterogenic clinical response, the inability to completely coun-
teract the disease, and the extremely high costs.26–29 Three 
pathogenic GAA variants with different effects on cryptic splic-
ing were analyzed, and this enabled the successful design 
of AONs that promoted splicing correction. The pipeline from 
splicing analysis to AON-based splicing correction may pro-
vide a basis for personalized medicine in human disease.
Results
Unbiased splicing analysis of all exons identifies aberrant 
splicing from an unknown GAA allele in patient 1
Patient 1 was diagnosed with Pompe disease based on a 
deficiency of GAA enzymatic activity in fibroblasts and leu-
kocytes (Table 1). Standard diagnostic DNA analysis, which 
includes Sanger sequencing of exons and short flanking 
intronic regions, identified the c.-32-13T>G (IVS1) GAA vari-
ant on one allele,9 but the pathogenic variant on the second 
allele was not identified (Figure 1a). We then applied our 
splicing assay (ref. 15) to test whether the unknown variant 
may be a regulatory or deep intronic splicing variant. Flanking 
exon polymerase chain reaction (PCR) analysis of all spliced 
GAA exons showed the expected aberrant splice products 
for exon 2 caused by the IVS1 variant, including a full exon 
2 skip, a partial exon 2 skip, and leaky wild type splicing 
(Figure 1b).15,30,31 Amplification of exons 15 and 16 revealed 
several higher molecular weight PCR products of low abun-
dance that were not normally observed in cells from healthy 
controls.15 To identify these, the exon 15 PCR products were 
directly processed by Topo cloning, and 93 clones were ana-
lyzed by Sanger sequencing. Four mRNAs were identified 
(Figure 1c and Supplementary Figure S1a). All aberrantly 
spliced products (1–3) utilized a cryptic splice acceptor in 
intron 15 at c.2190–344, and showed inclusion of various 
parts of intron 15. Product 1 included the downstream intronic 
region up to the splice acceptor of exon 16. This product con-
tains a premature stop codon and is likely to undergo mRNA 
decay, in agreement with the low abundance of this product. 
Product 2 and 3 included a small part of intron 15 by using 
the cryptic splice donor sites at c.2190–282 and c.2190–300, 
respectively. Product 2 contained the same premature stop 
codon as product 1, and was likely degraded as well. In prod-
uct 3, the reading frame remained intact. Therefore, the low 
abundance of the PCR product suggests minimal usage of 
the c.2190–300 splice site. Product 4 contained the canoni-
cal splice junctions and was the most abundant product of 
exon 15 amplification. It should be noted that the canonically 
spliced exon 15 product is also expressed from the IVS1 
allele. No unique sequence of product 1′ could be identified. 
However, this product disappeared by adapting the final cool-
ing step of the PCR reaction, suggesting that it represented 
a conformational variant (see Supplementary Figure S1b). 
The distribution of clones was: product 4 (canonical): 75 
clones; product 1 and 1′: 8 clones; product 3: 6 clones; and 
product 2: 4 clones.
Next, exon internal reverse-transcriptase-quantitative PCR 
(RT-qPCR) analysis of exons 2 to 20 was performed to quan-
tify aberrant splicing in cells from patient 1. All exons were 
expressed at similarly low levels of up to 12% compared 
with a healthy control (Figure 1d). The IVS1 GAA variant is 
known to allow 10–15% leaky wild type splicing.9,15,30–32 This 
suggests that the majority of GAA expression is derived from 
the IVS1 allele, and that the second allele containing the 
unknown GAA variant was expressed at much lower levels. 
Taken together, splicing analysis of all exons explained why 
patient 1 was diagnosed with Pompe disease, despite the 
lack of identification of the second GAA allele.
The newly identified deep intronic variant c.2190-345A>G 
causes aberrant splicing in patient 1
To identify which GAA DNA variant could be responsible for 
aberrant splicing of exon 15 and 16, we first analyzed the 
sequences of the aberrantly spliced mRNA products 1–4. 
This failed to show any potentially pathogenic GAA variant. 
Then, we analyzed the genomic DNA surrounding the cryp-
tic splices utilized in products 1–3. This revealed the pres-
ence of a heterozygous A > G variant at −1 relative to the 
cryptic splice acceptor site at c.2190–344 (Figure 1e). The 
Table 1 Patient characteristics
Variant allele 1 Variant allele 2
GAA activity in primary fibroblasts with 4-MU 
as substrate (nmol 4-MU/hour/mg protein)
Age at diagnosis 
(years) Onset
Patient 1 c.-32-13T>G ? = c.2190-345A>G 11.2 62 Adult
Patient 2 c.-32-13T>G ? = c.2190-345A>G 12.5 66 Adult
Patient 3 c.1552-3C>G c.1552-3C>G 12.6 16 Juvenile
Patient 4 c.1256A>T c.1551+1G>T 5.4 1.3 Juvenile
The question marks are deliberately used to indicate that this allele was previously unknown.
Reference GAA transcript for cDNA annotation is RefSeq NM_000152.3.
www.moleculartherapy.org/mtna
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intronic variant was missed by standard diagnostic sequence 
analysis because of its deep intronic location (Figure 1f, 
regions sequenced by standard diagnostics are indicated in 
gray). Its location close to the cryptic splice acceptor site sug-
gested that it was involved in mediating the aberrant splicing 
observed in cells from patient 1.
To test the effect of the c.2190-345A>G GAA variant on 
splicing, we used splicing prediction programs and minigenes. 
Alamut software, which includes five different algorithms to 
identify either 3′ or 5′ splice sites, predicted the generation of 
a strong splice acceptor site at c.2190–344 in the presence 
of the c.2190-345A>G variant (Figure 2a). This acceptor site 
was identical to the site identified in the aberrantly spliced 
products 1–3 of patient 1. Its predicted strength was simi-
lar to the strength of the canonical exon 16 splice acceptor 
site (compare Figure 2a and Supplementary Figure S2a). 
Figure 1  Identification of a deep intronic pathogenic variant in patient 1 using the splicing assay. (a) Scaled cartoon of acid 
α-glucosidase (GAA) allele 1 from patient 1 carrying the c.-32-13T>G (IVS1) variant. Coding exons are indicated in yellow, untranslated 
regions in brown. Lines represent introns. Areas in gray indicate the regions that are sequenced as part of standard diagnostic practice. 
(b) Flanking exon reverse-transcriptase-polymerase chain reaction (RT-PCR) of all GAA coding exons. Asterisks indicate known aberrant 
splicing products caused by the IVS1 variant. Products 1–4 indicate novel mRNA products. Product 1′ refers to a secondary structural variant 
of product 1 (see Supplementary Figure S1b). (c) Cartoon of splicing products 1–4. Boxes indicate exonic regions, (dashed) lines represent 
intronic regions. Aberrant splicing events are indicated in red. (d) Exon internal RT-quantitative PCR analysis of GAA exons 2–20. Data are 
normalized for β-actin and for a healthy control. Data represent means of three technical replicates ± SD. (e) Sequence analysis of genomic 
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The region around the cryptic donor sites identified in prod-
ucts 1–3 was also scrutinized and this resulted in a moder-
ately strong prediction of a splice donor site at c.2190–300 
(used in product 3); a strong prediction of a splice donor 
at c.2190–287 (not detected in vivo); and a weak predic-
tion (below the diagnostic threshold) of a splice donor site 
at c.2190–282 (used in product 2) (see Supplementary 
 Figure S2b). Some of these potential splice donor sites were 
indeed utilized in vivo in a subset of mRNAs. In summary, 
splicing prediction programs uniformly predicted the genera-
tion of the new splice acceptor at c.2190–344 in response to 
the c.2190-345A>G variant, while prediction of splice donor 
sites was variable.
Next, minigenes were used to test the pathogenic nature 
of the c.2190-345A>G variant. Two minigenes including the 
genomic DNA region spanning GAA exon 15 to 17 were gen-
erated, one wild type (c.2190-345A) and one containing the 
variant (c.2190-345A>G, Figure 2b). These constructs were 
transfected in HEK293T cells, and GAA exon 16 splicing was 
analyzed using flanking exon RT-PCR. Endogenous HEK293T 
transcripts were circumvented by usage of a reverse primer 
specific to the minigene backbone. In the wild type minigene, 
a single product for amplification of exon 16 was detected 
that represented canonical exon 16 splicing (product 8, 
 Figure 2c,d and Supplementary Figure S2c). This prod-
uct was absent from untransfected cells, demonstrating that 
it was derived from the minigene. In contrast, the minigene 
containing the c.2190-345A>G variant failed to show expres-
sion of the canonical exon 16 splicing product, but showed 
expression of multiple alternative products (Figure 2c). The 
exon 16 PCR product was Topo cloned, and sequence analy-
sis of 16 clones confirmed absence of the wild type product. 
Similar to endogenous exon 16 splicing in primary fibroblasts 
from patient 1, all aberrant products utilized the c.2190–344 
splice acceptor in combination with various cryptic splice 
donor sites (Figure 2d and Supplementary Figure S2c). 
Product 5 contained intron retention from c.2190–344 toward 
exon 16 (three clones); product 6 showed usage of the cryptic 
splice donor at c.2190–282 (eight clones); product 7 used a 
cryptic splice donor at c.2190–287 (two clones) (Figure 2d 
and Supplementary Figure S2c). These findings indicate 
that the c.2190-345A>G variant causes aberrant splicing of 
GAA intron 15 and represents the new pathogenic GAA vari-
ant in patient 1. The unbiased analysis of splicing in cells from 
patient 1 has enabled the identification of aberrant splicing 
and the associated genomic DNA variant that was missed by 
standard diagnostic sequencing.
Splicing correction by AONs in cells derived from patient 
1 and a sibling, patient 2
Previously, AONs have been used to modulate pre-mRNA 
splicing. A relatively straightforward approach has been to 
Figure 2 Assessment of the pathogenic nature of the c.2190-345A>G variant. (a) In silico prediction of the effect of the c.2190-345A>G 
variant on the generation of a 3′ cryptic splice site. Percentages indicate relative scores of strength per algorithm. (b) Cartoon of the minigenes 
containing the c.2190-345A or c.2190-345G variants. (c) Reverse-transcriptase-polymerase chain reaction (RT-PCR) analysis following 
transfection of minigenes into HEK293T cells. The reverse primer is specific for minigene mRNA as indicated in d. Products 5–8 indicate 
sequenced PCR products. Product 5′ refers to a secondary structural variant of product 5. Three biological replicates are shown. (d) Cartoon 
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block canonical splice sites to circumvent a variant hotspot 
and restore the reading frame, such as in DMD. AONs that 
bind to a splice site at the pre-mRNA can promote skipping of 
the splice site, which often results in utilization of another avail-
able (cryptic) splice site. We reasoned that a similar approach 
may be used to prevent utilization of a cryptic splice site such 
as the one generated by the c.2190-345G>A variant in patient 
1. To test this, we first analyzed the feasibility of AON-medi-
ated splicing modulation of pre-mRNA in primary fibroblasts. 
A control phosphorodiamidate morpholino oligonucleotide 
(PMO)-based AON was designed that targets the splice 
donor site of exon 4 in Cyclophilin A (CypA) pre-mRNA (AON 
CypA) (see Supplementary Figure S3a; based on ref. 33). 
AON CypA efficiently promoted skipping of CypA exons 3 
and 4 in fibroblasts from patient 1 as analyzed by RT-PCR 
(see Supplementary Figure S3b) and RT-qPCR (see Sup-
plementary Figure S3c). This demonstrated robust splicing 
modulation using PMO-based AONs in primary fibroblasts. 
Next, we designed an AON that targeted the cryptic splice 
site at c.2190–344 (AON intron 15; Figure 3a). Transfection 
of AON intron 15 in fibroblasts from patient 1 resulted in lower 
levels of endogenous aberrant splice products 1, 2, and 3, and 
higher abundance of canonical splice product 4, as shown by 
semiquantitative exon flanking RT-PCR analysis (Figure 3b). 
Mock transfection or transfection with AON CypA showed no 
effect. Quantitative RT-qPCR analysis was then performed to 
quantify changes in GAA splicing. Changes in wild type splic-
ing were quantified using primers spanning the GAA exon 
1-exon 2 splice junction. Low-abundant aberrantly spliced 
products were quantified using a forward primer annealing 
to exon 15 and a reverse primer that anneals to the common 
intronic region included in all aberrant splice products 1–3 
(Figure 3c, lower panel). Treatment with AON intron 15 pro-
moted splicing toward canonical GAA mRNA, while it inhib-
ited aberrant GAA splicing (Figure 3c). Mock transfected 
cells or cells transfected with AON CypA showed no effect 
on GAA splicing. The effect of AON intron 15 treatment on 
GAA enzymatic activity was then assessed, and this showed 
a more than twofold enhancement (Figure 3d). Importantly, 
this increase would result in a residual enzymatic activity that 
is above the disease threshold of 20% of control, suggesting 
that the AON intron 15-mediated splicing correction was suf-
ficient to alleviate Pompe disease in cells from patient 1.
A sibling of patient 1, patient 2, was also diagnosed with 
Pompe disease. This patient contained the IVS1 GAA vari-
ant but also lacked identification of the second pathogenic 
GAA allele using standard diagnostic analysis. Genomic 
DNA analysis showed that the unknown allele of patient 2 
was c.2190-345A>G, identical to the second allele of patient 
1 (see Supplementary Figure S4a). Flanking exon RT-
PCR analysis of exon 16 in primary fibroblasts indicated 
the same aberrant splicing products compared with patient 
1 (see Supplementary Figure S4b). Treatment with AON 
intron 15 resulted in a similar correction of splicing compared 
with patient 1, as shown by RT-PCR (see  Supplementary 
 Figure S4b) and RT-qPCR (see Supplementary 
 Figure S4c). Also the GAA enzymatic activity was enhanced 
by AON intron 15 treatment to 250% compared with mock 
transfection (see Supplementary Figure S4d), similar to 
patient 1. The results with patient 2 confirm the feasibility of 
Figure 3 Correction of aberrant splicing in fibroblasts from patient 1 using an antisense oligonucleotide (AON). (a) Cartoon depicting 
the region in the acid α-glucosidase (GAA) pre-mRNA that was targeted with AON intron 15. (b) Flanking exon reverse-transcriptase-
polymerase chain reaction (RT-PCR) analysis of GAA exon 16 in fibroblasts from patient 1 treated with AON intron 15. AON CypA was used 
as a control for AON treatment (see Supplementary Figure S3). Cartoons depict spliced mRNAs. Primer locations are indicated. Three 
biological replicates are shown. (c) RT-quantitative PCR (qPCR) analysis of the experiment outlined in b. Primers used for specific amplification 
of canonical (exon 1–exon 2) or aberrant (exon 15–intron 15) GAA mRNA are indicated in the cartoon below the graph. Data are normalized 
for β-actin and for mock transfection. Data represent mean ± SD of three biological replicates (**P = 0.01). (d) GAA enzymatic activity of patient 
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splicing correction by repression of the newly formed, deep 
intronic cryptic splice site at c.2190–344.
Inhibition of a natural intronic cryptic splice acceptor to 
correct splicing in cells derived from patient 3
To test whether the blocking of cryptic splice sites by AONs 
may represent a general approach to correct splicing in 
Pompe disease, we examined two additional patients.
Patient 3 (Table 1) represents an example in which an 
intronic GAA variant (homozygous c.1552-3C>G,15,34) weak-
ens a canonical splice site (splice acceptor of exon 11), 
which promotes utilization of a nearby cryptic splice site 
(c.1552-30, Figure 4a). We hypothesized that blockage of 
this cryptic splice site with an AON may enhance the prob-
ability of utilizing the canonical splice site. The details of aber-
rant splicing in fibroblasts of this patient have been described 
Figure 4 Antisense oligonucleotides (AON)-mediated correction of cryptic splicing in fibroblasts from two additional patients. (a) 
Cartoon depicting the region in the acid α-glucosidase (GAA) pre-mRNA of patient 3 that was targeted with an AON. This patient utilizes a 
cryptic splice site at c.1552-30 due to a homozygous variant c.1552-3C>G as described previously.15,35 The sequence of AON intron 10 is 
shown. (b) Flanking exon reverse-transcriptase-polymerase chain reaction (RT-PCR) analysis of GAA exon 10 in fibroblasts from patient 3 
that were treated with AON intron 10. Cartoons depict spliced mRNAs. Primer locations are indicated. Three biological replicates are shown. 
+ represents analysis of a healthy control. (c) RT-quantitative PCR (RT-qPCR) analysis of GAA exon 10–exon 11 expression in fibroblasts 
from patient 3 treated with AON intron 10. The forward primer anneals to GAA exon 10 and the reverse primer anneals to the GAA exon 
10–11 junction for specific detection of canonical exon 10–11 splicing. Data are normalized for β-actin and for mock transfection and represent 
mean ± SD of three biological replicates (*P = 0.05). (d) GAA enzymatic activity in patient 3 fibroblasts transfected with AON intron 10. Data 
represent mean ± SD of three biological replicates (*P = 0.05). (e) Cartoon depicting the region in the GAA pre-mRNA of patient 4 that was 
targeted with an AON. This patient utilizes a cryptic splice site at c.1254 due to the c.1256A>T variant as described previously.15 The sequence 
of AON exon 8 is shown. (f) Flanking exon RT-PCR analysis of GAA exon 9 on fibroblasts from patient 4 transfected with AON exon 8. Primers 
indicated in the cartoon specifically amplify canonically spliced GAA exon 8 mRNA from the allele harboring the c.1256A>T variant. Three 
biological replicates are shown. + represents analysis of a healthy control. (g) RT-qPCR analysis of GAA exon 8 – exon 10 expression in 
fibroblasts from patient 4 treated with AON exon 8. Primers only amplify canonically spliced GAA exon 8 mRNA from the allele harboring the 
c.1256A>T variant. Data represent mean ± SD of three biological replicates (***P = 0.001). (h) GAA enzymatic activity in patient 4 fibroblasts 
transfected with AON exon 8. Data represent mean ± SD of three biological replicates (***P = 0.001). Reprinted from refs. 15 and 35 with 
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by us previously (patient 6 in ref. 15). We now performed Topo 
cloning of cDNA products derived from flanking exon PCR 
of exon 10 (see Supplementary Table S1, -AON), and this 
resulted in the identification of two additional splicing prod-
ucts (10 and 11 in Figure 4b). All identified splicing products 
include: retention of intron 10 (product 9; reading frame dis-
rupted), splicing from the canonical splice donor site at exon 
10 to a natural cryptic splice acceptor at c.1552-30 in intron 
10 (product 10, reading frame intact), splicing from a natural 
splice acceptor at c.1537 in exon 10 to a cryptic splice accep-
tor at c.1552-30 (product 11; reading frame intact), leaky wild 
type splicing (product 12), and skipping of exon 10 plus utili-
zation of the cryptic splice acceptor at c.1552-30 (product 13; 
reading frame intact) (Figure 4b cartoons and Supplemen-
tary Figure S5a).
AON intron 10 was designed to target the cryptic splice 
site at c.1552-30 (Figure 4a). Transfection of this AON in 
fibroblasts from patient 3 caused a reduction of expression 
of aberrantly spliced mRNAs (products 9–11 and 13), while 
canonical spliced mRNA (product 12) seemed enhanced, as 
analyzed by flanking exon PCR of exon 10 (Figure 4b). This 
was also evident from the numbers of Topo clones derived 
from this PCR: without AON treatment, 49% of clones con-
tained wild type exon 10 spliced cDNA, while treatment with 
AON intron 10 yielded 80% wild type cDNA clones (see Sup-
plementary Table S1). It should be noted that product 9 (full 
intron 10 retention) is out of frame and is likely subject to 
mRNA degradation, which prevents an estimation of the total 
amount of transcripts produced. Both flanking exon RT-PCR 
and Topo cloning can only be considered semiquantitative 
methods. To quantify the effect of AON intron 10, RT-qPCR 
analysis was performed using a primer that anneals to the 
boundary of exon 10/11, as this distinguishes wild type from 
aberrant products (Figure 4c, lower panel). This confirmed 
that AON intron 10 enhanced canonical exon 10 splicing 
with 50% (Figure 4c). In agreement, a modest but significant 
increase of 1.3-fold of GAA enzymatic activity was detected 
in cells treated with AON intron 10 (Figure 4d). This patient 
has a considerable residual GAA activity (12.6 nmol/hour/
mg, representing ~10% of healthy control values), and an 
enhancement of 130% elevates GAA activity to levels closer 
to the disease threshold of ~20% of healthy control. Taken 
together, these results show that aberrant splicing caused by 
a splice site variant can be at least partially corrected by pre-
venting the utilization of a nearby located cryptic splice site 
using AONs.
Correction of aberrant splicing from a newly formed 
exonic splice donor site in cells derived from patient 4
To test whether it is also possible to modulate splicing by 
blocking a newly formed cryptic splice site formed at an 
exonic location, we examined patient 4. This patient car-
ries the c.1256A>T missense GAA variant on allele 1, which 
leads to the generation of an exonic cryptic splice donor site 
at c.1254 in exon 8 (patient 8 in ref. 15; Figure 4e, Sup-
plementary Figure S5b). Products from this allele include 
skipping of the 3′ part of exon 8. The second allele of this 
patient contains another GAA splicing variant, c. 1551+1G>T, 
which causes skipping of exon 10 (ref. 15; Supplementary 
Figure S5b). We hypothesized that blocking of the cryptic 
splice site at c.1254 with an AON may restore normal splic-
ing of the c. 1256A>T allele. First, we tested the possibility 
that the c.1256A>T missense (p.D419V) variant, which would 
still be present in the splice-corrected mRNA, affects GAA 
enzymatic activity. To test this, the GAA cDNA was cloned 
into an expression vector, and the c.1256A>T variant was 
introduced by site directed mutagenesis. Transfection into 
HEK293T cells followed by measurement of GAA enzymatic 
activity showed that the c.1256A>T variant did not impair 
GAA enzymatic activity (see Supplementary Figure S5c). 
This suggests that its pathogenic effect can be solely attrib-
uted to its effects on pre-mRNA splicing. Next, AON exon 
8 was designed complementary to the cryptic splice site 
including the variant at c.1256 (Figure 4e, variant sequence 
in red). AON exon 8 was transfected in primary fibroblasts 
from patient 4, and the effect on GAA mRNA expression 
and GAA enzymatic activity was determined. Flanking exon 
PCR was performed for exon 9 using primers designed to 
specifically detect splicing correction from the c.1256A>T 
allele with minimal interference from the c.1551+1G>T allele. 
This was achieved by using a forward primer that anneals 
to the 3′ part of exon 8, which is largely skipped in mRNA 
from the c.1256A>T allele, and a reverse primer that anneals 
to exon 10, which is completely skipped in mRNA from the 
c.1551+1G>T allele (Figure 4f). AON exon 8 enhanced the 
expression of canonically spliced exon 8 from the c.1256A>T 
allele (product 14, Figure 4f). Quantitative analysis using 
RT-qPCR with similar allele-specific primers confirmed that 
AON exon 8 enhanced expression of the c.1256A>T allele 
with 2.3-fold (Figure 4g). Besides promoting canonical exon 
8 splicing, AON exon 8 also caused skipping of exon 8, as 
shown by flanking exon PCR of exon 8 (see Supplementary 
Figure S5d). The net result of this effect was a partial correc-
tion of the splicing effect of the c.1256A>T variant. This is fur-
ther discussed in the legend to Supplementary Figure S5d.
In agreement with the mRNA analysis, GAA enzymatic 
activity was increased 2 fold as the result of AON exon 8 
treatment (Figure 4h). This patient showed a relatively low 
GAA enzymatic activity of 5.4 nmol/hour/mg (4.4% of healthy 
control) and a juvenile disease onset. Elevation of the GAA 
enzymatic activity with a factor 2 is expected to attenuate the 
onset and severity of Pompe disease. In summary, it is pos-
sible to redirect aberrant splicing toward canonical splicing 
by targeting a cryptic splice site formed by a variant at an 
exonic location.
Discussion
Assay for splicing analysis and genotyping
The assessment of a gene of interest for possible splicing 
defects can provide both qualitative and quantitative informa-
tion on aberrant splicing.15 This is important for establishing 
the pathogenic nature of a variant, with implications for diag-
nostics, genetic counseling, prediction of disease severity, 
and the development of novel treatment options. The splicing 
assay can also be used to identify deep intronic variants that 
have been missed by standard diagnostic DNA sequenc-
ing. Especially in countries in which a diagnosis requires 
the identification of two pathogenic variants to be eligible for 
therapy, as is the case with enzyme replacement therapy for 
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Pompe disease, this information can have a serious impact 
on treatment options for the patient. A rather straightforward 
flow has been applied here to identify a deep intronic vari-
ant. This started with the detection of aberrant splicing using 
unbiased, PCR-based analysis of all exons (Figure 5). It is 
important to note that also small amounts of aberrant mRNA 
products should be analyzed as these may be out of frame 
and subject to mRNA decay, as is the case in patient 1. Next, 
the region surrounding the novel splice sites was sequenced 
at the genomic DNA level. This revealed a potential splic-
ing variant. Third, the pathogenic effect of the variant was 
confirmed by in silico analysis and using a minigene con-
struct (Figure 5). This approach improves standard diag-
nostic practice and provides a potential basis for therapeutic 
development.
The use of RNA sequencing-based methods for splicing 
analysis of patients may play an increasingly important role 
in the future.35–37 However, at present, there are several dis-
advantages of using RNA sequencing-based techniques for 
diagnostics. In particular, to fully assess aberrant splicing of 
a particular gene in a quantitative manner, deep sequenc-
ing combined with bioinformatics analysis is required, which 
is rather expensive. The present PCR-based assay can be 
standardized and is fast, cheap, and sensitive. A useful addi-
tion may be the implementation of new techniques such as 
single molecule real-time DNA sequencing.38 This could be 
applied to cDNA, for example to determine whether patho-
genic variants reside on the same allele or are compound 
heterozygous, a question that could not be addressed for 
patients 1 and 2 due to the absence of DNA from the parents.
Disturbance of the splicing equilibrium by point variants
It is intriguing that a single point variant can generate a 
strong splice site as is the case for patient 1. This is in line 
with the fact that the sequence requirements for the gen-
eration of a potential splice site are relatively limited.13 The 
decision to utilize a splice site can depend on many aspects 
of gene expression, including the speed of RNA pol II tran-
scription, cis-acting sequences in the pre-mRNA, pre-mRNA 
structure, chromatin modifications, and expression levels of 
splicing proteins.13,14 It is therefore very difficult to predict the 
outcome of splicing based on in silico analysis of splice site 
strength. In patient 1 and 2 the formation of a new 3′ splice 
site not only results in retention of the downstream intronic 
sequence, but also in the utilization of two natural cryptic 5′ 
splice sites (see Supplementary Figure S2b). The 10–15% 
leaky wild type splicing detected in these patients is likely 
derived from the IVS1 allele, which is known to have this level 
of normal splicing.9,15,30,31 It should be noted that we could 
not formally prove that the IVS1 and c.2190-345A>G were 
compound heterozygous variants, as genomic DNA from the 
parents of patients 1 and 2 could not be obtained. However, 
the combined evidence obtained here strongly suggests that 
this is the case. In patient 3, the weakening of the canonical 
3′ splice site of exon 11 is straightforward, but the outcome 
with at least 3 different splicing products and the involvement 
of a nearby cryptic splice site was difficult to anticipate.15 
Patient 4 illustrates that missense variants can also affect 
splicing. In fact, recent evidence suggests that this phe-
nomenon is rather frequent and has been estimated to be 
the case in ~20% of all missense variants.2–4 In this patient, 
aberrant splicing appeared to be solely responsible for the 
pathogenic effect of the c.1256A>T variant, as the enzymatic 
activity of the mutated protein was similar to wild type GAA 
in cDNA expression analysis. Taken together, point variants 
can induce complex changes in alternative splicing that are 
difficult to predict but can be characterized using PCR-based 
analysis of all exons.
Targeted splicing correction using AONs
The information obtained with the splicing assay can directly 
be used to design AONs directed toward inhibition of cryp-
tic splicing by targeting the identified cryptic splice site 
(Figure 5). This was done in the case of patient 1 and 2. In 
primary fibroblasts from these patients, the enhancement of 
GAA enzymatic activity after treatment with AON was suf-
ficient to reach levels above the Pompe disease threshold of 
20% activity of healthy controls. This is further illustrated by 
the experience in our diagnostic center, at which all Pompe 
patients in the Netherlands are diagnosed. A combination of 
clinical and biochemical parameters applied to >200 patients 
and >300 healthy individuals showed a patient range to be 
0–20 nmol/hour/mg, and a normal range from 40–180 nmol/
hour/mg (ref. 39 and diagnostics department, Erasmus MC). 
This suggests that the AON designed to correct splicing in 
Figure 5 Pipeline for the identification and targeting of aberrant 
splicing events as applied to Pompe disease. The splicing assay 
consists of unbiased mRNA analysis of all coding exons by reverse-
transcriptase-quantitative PCR and Sanger sequencing.15 The 
results aid in diagnostics (left panel), but also provide the basis for 
the development of antisense oligonucleotides (AONs) that repress 
the utilization of natural or newly formed cryptic splice sites (right 
panel). Reprinted from ref. 15 with permission of the publisher.
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both patients has the potential to restore GAA enzyme levels 
toward healthy control levels. It should be noted that the cor-
rection of glycogen storage by AONs in cells in culture can-
not be studied at present, because cells from juvenile/adult 
onset Pompe patients do not show glycogen accumulation 
in vitro. This may imply that additional factors are required 
that are involved in lysosomal pathology in juvenile/adult 
onset Pompe disease. In agreement, several studies includ-
ing our own report on the strongly heterogeneous disease 
onset and progression of juvenile/adult Pompe patients, also 
when they have identical GAA genotypes.40–42
A priori, it was not always obvious that AON mediated 
repression of cryptic splicing would enhance canonical 
splicing. In the case of patients 1 and 2, we anticipated that 
repression of a deep intronic, newly formed splice site would 
restore canonical splicing, as was indeed observed. How-
ever, patients 3 and 4 represented more challenging cases.
In patient 3, the point variant was located near a 3′ splice 
site, which resulted in weakening of the canonical splice site 
and utilization of the c.1552-30 cryptic splice site. Another 
observed event as a consequence of the c.1552-3C>G 
variant was retention of intron 10. It was not clear whether 
blocking of the cryptic splice site with an AON would pro-
mote canonical splicing or intron retention. This depended 
on the question whether the canonical splice site was still 
partially functional despite the nearby c.1552-3C>G variant. 
In this case, the AON blocked utilization of the cryptic splice 
site without promoting other detectable forms of aberrant 
splicing. This showed that the canonical splice site was still 
partially functional, suggesting a competition model in which 
the strongest nearby splice site is preferred. Competition for 
splice site usage is thought to play an important role in the 
outcome of pre-mRNA splicing, as is the distance to the next 
available splice site.13,14 The fact that repression of the natural 
upstream cryptic splice site promoted splicing to a weakened 
canonical splice site is encouraging and may suggest a gen-
eral strategy for similar cases.
In patient 4, the targeting of an AON to an exonic region 
represented a challenge, as this has the potential to interfere 
with protein translation.43 We found no evidence for this, as 
canonical splicing was increased with a concomitant increase 
in GAA protein activity. However, the AON targeted to exon 
8 resulted in a new equilibrium of AS, in which both canoni-
cal splicing and aberrant splicing were altered. This illustrates 
that AON targeting of cryptic splice sites may induce new 
splice forms, and it underscores the importance of testing for 
this possibility. In this patient, the AON-induced changes in 
AS were advantageous as the c.1256A>T allele showed an 
improvement to 195%, while the effect on exon 8 splicing of 
the second allele was irrelevant as this already was affected 
by aberrant splicing of exon 10.
Application of AONs in human disease
To translate the present results to a clinical setting, more pre-
clinical testing is required. Extensive work has been performed 
for a number of disorders including spinal muscular atrophy and 
DMD (at the level of clinical trials), and Hutchinson-Gilford pro-
geria syndrome19 and type I Usher syndrome20 (using animal 
models). These studies have shown that AONs can enhance 
expression of the gene of interest following various routes of 
administration. It is important to consider the disease-specific 
aspects for AON-based treatment options. For instance, in the 
case of DMD, the maximal effect that can be reached using 
an exon skipping strategy is the milder Becker’s Muscular Dys-
trophy phenotype due to the expression of a truncated dystro-
phin protein, and this is still a serious condition. In addition, in 
DMD or Becker’s Muscular Dystrophy, not only skeletal muscle 
is affected, but also cardiac muscle and the central nervous 
system, which are more difficult to target using AONs. Cellu-
lar uptake can be further enhanced by conjugation with cell 
penetrating peptides or octaguanidine dendrimers, which have 
been applied to PMO-based AONs and showed good efficacy 
in animal models.44–46 In contrast to the situation in DMD, AONs 
in Pompe disease have the potential to restore wild type GAA 
expression toward levels present in healthy individuals. In the 
childhood/adult form of the disease, skeletal muscle cells are 
the major cells affected without involvement of cardiac or neu-
ronal cells.47,48 This contrasts with classic infantile Pompe dis-
ease, in which hypertrophic cardiomyopathy is present at birth,25 
and cognitive decline may progressively develop.49,50 This study 
identifies AONs for childhood/adult onset Pompe patients. Fur-
ther studies are required to test the efficacy of these AONs to 
target skeletal muscle cells in vitro and in vivo. Interestingly, a 
recent study used AONs with a PMO backbone coupled to an 
arginine-rich cell penetrating peptide to target muscle glycogen 
synthase in a mouse model for Pompe disease, suggesting 
that it is feasible to use AONs for Pompe disease in vivo.46 The 
ongoing development of methods to enhance tissue delivery of 
AONs in vivo by changing the chemistry,51 charge,52 by coupling 
to cell penetrating peptides,21–23,44–46 or by using carriers such as 
exosomes or nanoparticles,53,54 is expected to further stimulate 
clinical testing of AONs. Current knowledge from recent clinical 
trials on the safety of AON backbones should help to facilitate 
further development of AONs, and to test whether AONs pro-
vides a valuable alternative or addition to enzyme replacement 
therapy in Pompe disease.
Materials and methods
Materials. Fetal Bovine Serum was purchased from GE Health-
care (Logan, UT). Penicillin/Streptomycin/Glutamine (p/s/g) and 
TryplE were purchased from Thermo Fisher Scientific (Waltham, 
MA). DMEM High Glucose was purchased from Lonza (Walk-
ersville, MD). DMSO Endoporter reagent and PMO-based 
AONs were purchased from Gene-Tools (Philomath, OR) and 
all other chemicals were purchased from Sigma Aldrich (Irvine, 
UK) unless otherwise stated.
Patients. Patients were diagnosed with Pompe disease at the 
Center for Lysosomal and Metabolic Diseases of the Erasmus 
MC, Rotterdam, The Netherlands. Diagnosis was based on 
GAA enzymatic activity in leukocytes and/or fibroblasts, GAA 
variants, and clinical symptoms. Analysis was performed on 
anonymous patient material using informed consent.
Nomenclature. All references toward locations of variants 
and splice sites are made according to HGVS standards 
(http://www.hgvs.org/mutnomen/).55 The reference GAA tran-
script was RefSeq NM_000152.3.
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Generation of minigene and cDNA construct. For generation of 
the minigene containing the genomic GAA DNA region of GAA 
exon 15–17 (chr17:80113219-80117749, GRCh38/hg38), 
genomic DNA from a healthy control was amplified with PFU 
Ultra Hotstart polymerase (Agilent Technologies, Santa Clara, 
CA) and cloned in the pcDNA3.1(−)Myc-His A vector using 
the XbaI and NotI restriction sites. The c.2190-345A>G variant 
was introduced using the QuikChange II Site-Directed Muta-
genesis Kit (Agilent Technologies). The GAA cDNA expres-
sion construct (RefSeq NM_000152.3) was generated in the 
same vector, using restriction sites NheI and AflII, and the 
c.1256A>T variant was introduced using site directed muta-
genesis as above. All constructs were verified by sequence 
analysis (all primers used in Supplementary Table S2).
Cell culture and transfections. HEK293T cells and primary 
human fibroblasts were cultured in 10% FBS, 1× p/s/g and 
DMEM High Glucose. Transfection of minigenes and cDNA 
constructs was performed using Lipofectamine 2000 accord-
ing to the manufactures’ protocol. Cells were harvested 48 
hours after transfection. GAA cDNA expression was corrected 
for mRNA expression of the Neomycin cassette present on 
the pcDNA3.1 backbone using RT-qPCR analysis. Transfec-
tion of AONs was performed using 4.5 µl/ml endoporter in the 
medium at a concentration of 20 µmol/l AON. RNA and protein 
were harvested 3 and 5 days after transfection, respectively.
Splicing assay. The splicing assay was performed as 
described before.15 In short, RNA was isolated using the 
RNAeasy miniprep kit (Qiagen, Germantown, MD). RT-PCR 
was performed with 800 ng RNA input using iScript (Biorad, 
Hercules, CA) and FastStart Taq Polymerase (Roche, Pen-
zberg, Germany). qPCR was carried out using iTaq SYBR 
green supermix (Biorad,), and was performed on a cfx96rts 
cycler (Biorad). Primers are shown in Supplementary 
Table S2. β-actin was used as a reference gene. All primer 
sets used showed high efficiency and specificity based on 
melting-curve analysis and standard curve measurements.
In silico splice prediction. In silico prediction was carried out 
using Alamut Visual version 2.6.1, which uses five algorithms 
for predicting 5′ and 3′ splice junctions (description of algo-
rithms at http://www.interactive-biosoftware.com/doc/alamut-
visual/2.6/splicing.html) as described.15
GAA enzymatic activity. Enzymatic activity of the GAA pro-
tein was determined as previously described.33 In short, 
cell lysates were incubated with 4-methyl-umbelliferyl-α-d-
glucopyranoside (4-MU, Sigma) in citrate–phosphate buffer 
for 1 hour at 37°C, after which fluorescence was measured at 
365/448 nm with the Varioskan system (Thermo Fisher). The 
GAA enzymatic activity is dependent on cell culture condi-
tions. To correct for this, a control cell line was included in 
each experiment, and the GAA enzymatic activity was nor-
malized based on this control line.
Supplementary material
Figure S1. Sequence analysis and structural effects of GAA 
splicing products 1–4 identified in cells from patient 1.
Figure S2. In silico prediction and sequence analysis of GAA 
splicing products 5–8 in cells from patient 1.
Figure S3. Exon skipping in CypA pre-mRNA by an AON.
Figure S4. AON intron 15 restores GAA splicing in cells from 
patient 2, a sibling of patient 1.
Figure S5. Further analysis of patients 3 and 4.
Table S1. Number of products with and without AON treat-
ment of patient 1.
Table S2. Primers used for experiments.
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